Institut Pasteur Korea(IPK) is leading the development of COVID-19 treatment through drug repositioning research. IPK studied the antiviral efficacy of approx. 3,000 drugs, including US FDA-approved drugs, against the SARS-CoV-2 throughout cellular experiments, and identified drug candidates with excellent efficacy. Domestic and overseas clinical trials on these identified drugs are currently underway in collaboration with domestic pharmaceutical companies. In addition, recently, IPK reported that the COVID-19 drugs and drug candidates, including the drug candidates identified by IPK, exhibited in cell experiments equally effective antiviral efficacies against both early SARS-CoV-2 and its variants from the UK and South Africa. Here is a special article that introduces niclosamide and camostat, which are currently in a development pipeline after whose potent antiviral efficacy was confirmed through IPK’s research.

 
+ + + + +
 
Chosun Ilbo (2021.4.26)

Three treatments that can be applied to all patients are in development


Go to the article >>